YW3-56

• CAT Number: I038632
• CAS Number: 2309756-20-3
• Molecular Formula: C27H33Cl2N5O2
• Molecular Weight: 530.49
• Purity: 98%
• Synonyms: YW356; YW3 56; YW3-56
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: N-[(2R)-5-[(1-Amino-2-chloroethylidene)amino]-1-(benzylamino)-1-oxopentan-2-yl]-6-(dimethylamino)naphthalene-2-carboxamide Hydrochloride
• InChI: InChI=1S/C27H32ClN5O2.ClH/c1-33(2)23-13-12-20-15-22(11-10-21(20)16-23)26(34)32-24(9-6-14-30-25(29)17-28)27(35)31-18-19-7-4-3-5-8-19;/h3-5,7-8,10-13,15-16,24H,6,9,14,17-18H2,1-2H3,(H2,29,30)(H,31,35)(H,32,34);1H/t24-;/m1./s1
• InChIKey: DBGNVJZDXMWWQR-GJFSDDNBSA-N
• SMILES: O=C(C1=CC=C2C=C(N(C)C)C=CC2=C1)N[C@H](CCC/N=C(N)/CCl)C(NCC3=CC=CC=C3)=O.[H]Cl

YW3-56 (Cat No.: I038632) is a small-molecule inhibitor targeting PAD (peptidylarginine deiminase) enzymes, particularly PAD4, which play a key role in protein citrullination. By inhibiting PAD activity, YW3-56 disrupts abnormal citrullination processes linked to cancer progression, inflammation, and autoimmune diseases. It has shown antitumor effects in preclinical studies, including induction of autophagy and apoptosis in cancer cells. YW3-56 is valuable in epigenetic and immunological research, offering potential for therapeutic development in cancer and diseases involving dysregulated PAD activity and chromatin remodeling.

Reference

1: Liang Y, Pan B, Alam HB, Deng Q, Wang Y, Chen E, Liu B, Tian Y, Williams AM, Duan X, Wang Y, Zhang J, Li Y. Inhibition of peptidylarginine deiminase alleviates LPS-induced pulmonary dysfunction and improves survival in a mouse model of lethal endotoxemia. Eur J Pharmacol. 2018 Aug 15;833:432-440. doi: 10.1016/j.ejphar.2018.07.005. Epub 2018 Jul 5. PubMed PMID: 29981294; PubMed Central PMCID: PMC6195118.
2: Raup-Konsavage WM, Wang Y, Wang WW, Feliers D, Ruan H, Reeves WB. Neutrophil peptidyl arginine deiminase-4 has a pivotal role in ischemia/reperfusion-induced acute kidney injury. Kidney Int. 2018 Feb;93(2):365-374. doi: 10.1016/j.kint.2017.08.014. Epub 2017 Oct 20. PubMed PMID: 29061334; PubMed Central PMCID: PMC5794573.
3: Pan B, Alam HB, Chong W, Mobley J, Liu B, Deng Q, Liang Y, Wang Y, Chen E, Wang T, Tewari M, Li Y. CitH3: a reliable blood biomarker for diagnosis and treatment of endotoxic shock. Sci Rep. 2017 Aug 21;7(1):8972. doi: 10.1038/s41598-017-09337-4. PubMed PMID: 28827548; PubMed Central PMCID: PMC5567134.
4: He W, Zhou P, Chang Z, Liu B, Liu X, Wang Y, Li Y, Alam HB. Inhibition of peptidylarginine deiminase attenuates inflammation and improves survival in a rat model of hemorrhagic shock. J Surg Res. 2016 Feb;200(2):610-8. doi: 10.1016/j.jss.2015.09.008. Epub 2015 Sep 9. PubMed PMID: 26434505; PubMed Central PMCID: PMC4691393.
5: Wang S, Chen XA, Hu J, Jiang JK, Li Y, Chan-Salis KY, Gu Y, Chen G, Thomas C, Pugh BF, Wang Y. ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells. Mol Cancer Ther. 2015 Apr;14(4):877-88. doi: 10.1158/1535-7163.MCT-14-1093-T. Epub 2015 Jan 22. PubMed PMID: 25612620; PubMed Central PMCID: PMC4394025.
6: Zhu H, Wang Y, Wang Y, Zhao S, Zhao M, Gui L, Xu W, Chen XA, Wang Y, Peng S. Folded Conformation, Cyclic Pentamer, Nano-Structure and PAD4 Binding Mode of YW3-56. J Phys Chem C Nanomater Interfaces. 2013 May 16;117(19):10070-10078. PubMed PMID: 23795230; PubMed Central PMCID: PMC3685498.
7: Wang Y, Li P, Wang S, Hu J, Chen XA, Wu J, Fisher M, Oshaben K, Zhao N, Gu Y, Wang D, Chen G, Wang Y. Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity. J Biol Chem. 2012 Jul 27;287(31):25941-53. doi: 10.1074/jbc.M112.375725. Epub 2012 May 17. PubMed PMID: 22605338; PubMed Central PMCID: PMC3406678.